Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC By Ogkologos - July 22, 2025 497 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CREST study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Foster Teen With A Passion For Painting Is Patiently Waiting For... January 30, 2022 BREAKING: President Trump May Restore The WHO’s Funding, With Some Conditions May 18, 2020 Becoming My Own Advocate While Living With a Rare Cancer: A... April 27, 2023 Working Mom with Stage II Breast Cancer Receives Custom Wig Made... July 30, 2020 Load more HOT NEWS People with Cancer Say Access to Their Clinical Notes Is Valuable Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell... Happy Nurses Month! Puppy That Was Born Dead Becomes Therapy Dog for Cancer Patient
